Polyethylene glycol modified endostatin inhibitor composition
The invention relates to a polyethylene glycol modified endostatin inhibitor composition which comprises polyethylene glycol endostatin, a protector and a buffer system, wherein the dosage ratio of the polyethylene glycol endostatin to the protector is (1:10)-(10:1); and the buffer system is a phosp...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | JIANG GUIXIANG ZHAO QUN HUA YUYANG JIANG BOREN SONG WENTING CHEN QIANJIE REN JINSHENG |
| description | The invention relates to a polyethylene glycol modified endostatin inhibitor composition which comprises polyethylene glycol endostatin, a protector and a buffer system, wherein the dosage ratio of the polyethylene glycol endostatin to the protector is (1:10)-(10:1); and the buffer system is a phosphate buffer system. In the preparation process, when the phosphate buffer system is adopted as a buffer agent, the pH value of an obtained frozen-dry preparation is slightly changed, and storage and shelf stability of a product can be well benefited.
本发明涉及一种聚乙二醇修饰的血管内皮抑制素组合物，所述组合物包含聚乙二醇化血管内皮抑制素、保护剂和缓冲体系，其中所述的聚乙二醇化血管内皮抑制素与保护剂的质量比为1:10～10:1；所述的缓冲体系为磷酸盐缓冲体系；在制备过程中，当使用磷酸盐缓冲体系作为缓冲剂时，获得的冻干制剂的pH变化较小，十分有利于产品的储藏和货架稳定性。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN111346220A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN111346220A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN111346220A3</originalsourceid><addsrcrecordid>eNrjZLANyM-pTC3JqMxJzUtVSM-pTM7PUcjNT8lMy0xNUUjNS8kvLkksycxTyMzLyEzKLMkvUkjOzy3IL84syczP42FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFiclAU0vinf0MDQ2NTcyMjAwcjYlRAwCd-DEu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Polyethylene glycol modified endostatin inhibitor composition</title><source>esp@cenet</source><creator>JIANG GUIXIANG ; ZHAO QUN ; HUA YUYANG ; JIANG BOREN ; SONG WENTING ; CHEN QIANJIE ; REN JINSHENG</creator><creatorcontrib>JIANG GUIXIANG ; ZHAO QUN ; HUA YUYANG ; JIANG BOREN ; SONG WENTING ; CHEN QIANJIE ; REN JINSHENG</creatorcontrib><description>The invention relates to a polyethylene glycol modified endostatin inhibitor composition which comprises polyethylene glycol endostatin, a protector and a buffer system, wherein the dosage ratio of the polyethylene glycol endostatin to the protector is (1:10)-(10:1); and the buffer system is a phosphate buffer system. In the preparation process, when the phosphate buffer system is adopted as a buffer agent, the pH value of an obtained frozen-dry preparation is slightly changed, and storage and shelf stability of a product can be well benefited.
本发明涉及一种聚乙二醇修饰的血管内皮抑制素组合物，所述组合物包含聚乙二醇化血管内皮抑制素、保护剂和缓冲体系，其中所述的聚乙二醇化血管内皮抑制素与保护剂的质量比为1:10～10:1；所述的缓冲体系为磷酸盐缓冲体系；在制备过程中，当使用磷酸盐缓冲体系作为缓冲剂时，获得的冻干制剂的pH变化较小，十分有利于产品的储藏和货架稳定性。</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200630&DB=EPODOC&CC=CN&NR=111346220A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200630&DB=EPODOC&CC=CN&NR=111346220A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JIANG GUIXIANG</creatorcontrib><creatorcontrib>ZHAO QUN</creatorcontrib><creatorcontrib>HUA YUYANG</creatorcontrib><creatorcontrib>JIANG BOREN</creatorcontrib><creatorcontrib>SONG WENTING</creatorcontrib><creatorcontrib>CHEN QIANJIE</creatorcontrib><creatorcontrib>REN JINSHENG</creatorcontrib><title>Polyethylene glycol modified endostatin inhibitor composition</title><description>The invention relates to a polyethylene glycol modified endostatin inhibitor composition which comprises polyethylene glycol endostatin, a protector and a buffer system, wherein the dosage ratio of the polyethylene glycol endostatin to the protector is (1:10)-(10:1); and the buffer system is a phosphate buffer system. In the preparation process, when the phosphate buffer system is adopted as a buffer agent, the pH value of an obtained frozen-dry preparation is slightly changed, and storage and shelf stability of a product can be well benefited.
本发明涉及一种聚乙二醇修饰的血管内皮抑制素组合物，所述组合物包含聚乙二醇化血管内皮抑制素、保护剂和缓冲体系，其中所述的聚乙二醇化血管内皮抑制素与保护剂的质量比为1:10～10:1；所述的缓冲体系为磷酸盐缓冲体系；在制备过程中，当使用磷酸盐缓冲体系作为缓冲剂时，获得的冻干制剂的pH变化较小，十分有利于产品的储藏和货架稳定性。</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLANyM-pTC3JqMxJzUtVSM-pTM7PUcjNT8lMy0xNUUjNS8kvLkksycxTyMzLyEzKLMkvUkjOzy3IL84syczP42FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFiclAU0vinf0MDQ2NTcyMjAwcjYlRAwCd-DEu</recordid><startdate>20200630</startdate><enddate>20200630</enddate><creator>JIANG GUIXIANG</creator><creator>ZHAO QUN</creator><creator>HUA YUYANG</creator><creator>JIANG BOREN</creator><creator>SONG WENTING</creator><creator>CHEN QIANJIE</creator><creator>REN JINSHENG</creator><scope>EVB</scope></search><sort><creationdate>20200630</creationdate><title>Polyethylene glycol modified endostatin inhibitor composition</title><author>JIANG GUIXIANG ; ZHAO QUN ; HUA YUYANG ; JIANG BOREN ; SONG WENTING ; CHEN QIANJIE ; REN JINSHENG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN111346220A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>JIANG GUIXIANG</creatorcontrib><creatorcontrib>ZHAO QUN</creatorcontrib><creatorcontrib>HUA YUYANG</creatorcontrib><creatorcontrib>JIANG BOREN</creatorcontrib><creatorcontrib>SONG WENTING</creatorcontrib><creatorcontrib>CHEN QIANJIE</creatorcontrib><creatorcontrib>REN JINSHENG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JIANG GUIXIANG</au><au>ZHAO QUN</au><au>HUA YUYANG</au><au>JIANG BOREN</au><au>SONG WENTING</au><au>CHEN QIANJIE</au><au>REN JINSHENG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Polyethylene glycol modified endostatin inhibitor composition</title><date>2020-06-30</date><risdate>2020</risdate><abstract>The invention relates to a polyethylene glycol modified endostatin inhibitor composition which comprises polyethylene glycol endostatin, a protector and a buffer system, wherein the dosage ratio of the polyethylene glycol endostatin to the protector is (1:10)-(10:1); and the buffer system is a phosphate buffer system. In the preparation process, when the phosphate buffer system is adopted as a buffer agent, the pH value of an obtained frozen-dry preparation is slightly changed, and storage and shelf stability of a product can be well benefited.
本发明涉及一种聚乙二醇修饰的血管内皮抑制素组合物，所述组合物包含聚乙二醇化血管内皮抑制素、保护剂和缓冲体系，其中所述的聚乙二醇化血管内皮抑制素与保护剂的质量比为1:10～10:1；所述的缓冲体系为磷酸盐缓冲体系；在制备过程中，当使用磷酸盐缓冲体系作为缓冲剂时，获得的冻干制剂的pH变化较小，十分有利于产品的储藏和货架稳定性。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN111346220A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Polyethylene glycol modified endostatin inhibitor composition |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T16%3A17%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JIANG%20GUIXIANG&rft.date=2020-06-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN111346220A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |